Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA

Back

Most Accessed Articles

HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles open access plus

Volume: 17   Issue: 7
Pp: 637-649
Sarah L. Sammons, Donna L. Topping and Kimberly L. Blackwell
DOI: 10.2174/1568009617666170330120452

Order Reprints Order Eprints

Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies

Volume: 16   Issue: 9
Pp: 755-764
Senthamil R. Selvan, John P. Dowling, William K. Kelly and Jianqing Lin
DOI: 10.2174/1568009615666151030102250

Order Reprints Order Eprints

CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies

Volume: 17   Issue: 5
Pp: 423-444
Dariush Shanehbandi, Jafar Majidi, Tohid Kazemi, Behzad Baradaran and Leili Aghebati-Maleki
DOI: 10.2174/1568009617666170109151128

Order Reprints Order Eprints

Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review

Volume: 17   Issue: 7
Pp: 603-616
Nishi Karunasinghe, Jonathan Masters, Jack U. Flanagan and Lynnette R. Ferguson
DOI: 10.2174/1568009617666170330115722

Order Reprints Order Eprints

Chemotherapy and Cardiotoxicity in Hematologic Malignancies

Volume: 17   Issue: 4
Pp: 311-324
Antonio Stellitano, Roberta Fedele, Santina Barilla, Antonino Iaria, Carmelo Massimiliano Rao and Massimo Martino
DOI: 10.2174/1568009617666161121141607

Order Reprints Order Eprints

Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy

Volume: 17   Issue: 4
Pp: 344-356
Heena Singla, Sourav Kalra, Preeti Kheterpal, Vinod Kumar and Anjana Munshi
DOI: 10.2174/1568009616666161216094026

Order Reprints Order Eprints